Home > Insider Trading > Filing (0001144204-16-120040)

Filing Details

Accession Number:: 0001144204-16-120040
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-08-17 17:19:47
Reporting Period:: 2016-08-15

Filing Date:: 2016-08-17
Accepted Time:: 2016-08-17 17:19:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1607962	Rewalk Robotics Ltd.	RWLK	Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1661229	Jeff Dykan	C/O Rewalk Robotics, Ltd. 3 Hatnufa St. P.o. Box 161 Yokneam Ilit L3 20692203		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Par Value Nis 0.01 Per Share	Disposition	2016-08-15	43,765	$6.45	1,643,335	No	4	S	Indirect	By partnership
Ordinary Shares, Par Value Nis 0.01 Per Share	Disposition	2016-08-16	6,235	$6.42	1,637,100	No	4	S	Indirect	By partnership
Ordinary Shares, Par Value Nis 0.01 Per Share	Disposition	2016-08-16	50,000	$6.29	1,587,100	No	4	S	Indirect	By partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By partnership
No	4	S	Indirect	By partnership
No	4	S	Indirect	By partnership

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Ordinary Shares, Par Value Nis 0.01 Per Share	6,022	Indirect	ESOP

Footnotes

The disposed of securities consist of 32,807 Ordinary Shares sold by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and 10,958 shares sold by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife Israel").
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4000 to $6.5350, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The Reporting Person is a director of SCP Vitalife II GP, Ltd. ("SCP Vitalife GP"), which is the sole general partner of SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"). SCP Vitalife Associates is the sole general partner of each of SCP Vitalife and SCP Vitalife Israel, the direct beneficial owner of the Ordinary Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, except to the extent of his pecuniary interest therein.
The disposed of securities consist of 4,674 Ordinary Shares sold by SCP Vitalife and 1,561 shares sold by SCP Vitalife Israel.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.4000 to $6.4700, inclusive. The reporting person undertakes to provide to ReWalk, any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The disposed of securities consist of 37,481 Ordinary Shares sold by SCP Vitalife and 12,519 shares sold by SCP Vitalife Israel.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2100 to $6.4500, inclusive. The reporting person undertakes to provide to ReWalk, any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4.
As of August 16, 2016, SCP Vitalife Associates, as the general partner of SCP Vitalife and SCP Vitalife Israel, may be deemed to beneficially own 1,444,574 Ordinary Shares, which consist of 1,082,892 and 361,682 Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, respectively. SCP Vitalife GP is the general partner of SCP Vitalife Associates and, as such, shares voting and dispositive power over, and may be deemed to beneficially own, the Ordinary Shares held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own 1,587,100 Ordinary Shares, which consist of the Ordinary Shares as set forth in footnote (9) to this Form 4.
As of August 16, 2016, consists of 1,444,574 Ordinary Shares held by the foregoing entities due to the Reporting Person serving as a director of SCP Vitalife GP, as well as (i) 62,006 Ordinary Shares held by Vitalife Partners (Overseas) L.P., (ii) 20,506 Ordinary Shares held by Vitalife Partners (Israel) L.P., (iii) 20,733 Ordinary Shares held by Vitalife Partners (D.C.M) L.P. ("Vitalife Partners DCM", and together with Vitalife Partners (Overseas) L.P. and Vitalife Partners (Israel) L.P., the "Vitalife I Entities") and (iv) 39,281 Ordinary Shares currently held by the Office of the Chief Scientist of the State of Israel ("OCS"), that the Vitalife I Entities have the right to acquire from the OCS, due to the Reporting Person serving as a director of Vitalife Life Sciences Ltd., the general partner of Vitalife Partners Management L.P., which is the general partner of each of the Vitalife I Entities.
Represents 6,022 ordinary shares issuable upon the vesting of restricted stock units ("RSUs") granted on December 15, 2014 under the ReWalk 2014 Equity Incentive Plan. One-third, or 2,007 Ordinary Shares, of the RSUs vested on the first anniversary of the date of grant and the remaining RSUs vest in equal quarterly installments of 501 Ordinary Shares each starting one quarter after the first anniversary of the date of grant.